NCT05403177 Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)
| NCT ID | NCT05403177 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Health Network, Toronto |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2022-06-23 |
| Primary Completion | 2030-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2022-06-23 with a primary completion date of 2030-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients
Eligibility Criteria
Inclusion Criteria: 1. Patients with histological and/or cytological confirmation of blood or solid tumor malignancies. For tumour types where pre-surgical biopsy is not routinely performed to confirm a pathologic diagnosis of cancer, patients may consent to this protocol, but eligibility must be confirmed after pathology is finalized demonstrating presence of malignancy 2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through: 1. Already existing data that satisfies the minimal requirements of a gold standard case (refer to Table 1) 2. Have sufficient biospecimens (tumor and/or blood samples) available for more comprehensive molecular and immunophenotypic characterization 3. Patients who do not satisfy the required minimum data elements but would like to participate, maybe requested to donate blood and undergo a fresh biopsy if the archived Formalin-fixed paraffin-embedded (FFPE) samples are not available, or in cases where a fresh tumor biopsy is deemed necessary for molecular profiling. 4. Participating patients must agree to share their anonymized clinical and genomic data Exclusion Criteria: None.
Contact & Investigator
Lillian Siu, MD
PRINCIPAL INVESTIGATOR
University Health Network, Toronto
Frequently Asked Questions
Who can join the NCT05403177 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05403177 currently recruiting?
Yes, NCT05403177 is actively recruiting participants. Contact the research team at MOHCCN@uhn.ca for enrollment information.
Where is the NCT05403177 trial being conducted?
This trial is being conducted at Kingston, Canada, Ottawa, Canada, Toronto, Canada.
Who is sponsoring the NCT05403177 clinical trial?
NCT05403177 is sponsored by University Health Network, Toronto. The principal investigator is Lillian Siu, MD at University Health Network, Toronto. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.